The Next Frontier of Medicines for Cardioendocrine Diseases. Backed by Third Rock Ventures.
About the role
This is a key role within our Technical Operations team as we aggressively advance our first program towards late-stage development and our second program into early-stage clinical development. This role will report to the VP of Technical Development.
What they're looking for
- Specific experience with developing, scaling up, tech transferring downstream processes for CHO-derived monoclonal antibodies
- Previously experience of having worked with CDMOs with scope of work in process development, tech transfer and scale up
- Direct experience with at-scale manufacturing processes and equipment either through previous tech transfers or direct manufacturing operations experience
- Demonstrated ability to independently write technical reports based on sound data analysis and experimental design
- Demonstrated understanding of overall drug development workflow and how CMC can enable acceleration of drug development in a cross functional environment
- Knowledge of cGMPs, especially as related to a virtual environment where manufacturing is currently outsourced to third party vendors
More about this role
Marea Therapeutics is a clinical-stage biotechnology company based in South San Francisco with a growing pipeline of first-in-class therapies to address genetically validated cardioendocrine disease targets. Our therapies have the potential to serve as transformative treatment options for significant patient populations living with cardioendocrine diseases.
The company’s lead program, MAR001, is being developed for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels and elevated risk of acute pancreatitis. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR001 has demonstrated strong and a differentiated profile in patients and is approaching Phase 3 development. Our second clinical asset, MAR002, is a monoclonal antibody targeting excess growth hormone produced by the pituitary gland in the rare hormonal disorder, acromegaly. MAR002 has potential to become best-in-disease and is quickly progressing into Phase 2/3 clinical development. We also have a third asset that is swiftly advancing through research discovery, with DC...
Browse similar: Startup jobs · San Francisco Bay Area